Prof. Farhad Hafezi, MD, PhD, FARVO, has been appointed to the Editorial Board of EuroTimes, the official publication of the European Society of Cataract and Refractive Surgeons (ESCRS). This role further solidifies his contributions to ophthalmic research, education, and innovation.
Nikki Hafezi-Kristoffersen, MAS IP ETHZ, CEO of the ELZA Institute and executive at the MESCA Foundation, recently visited the Bukhara State Medical Institute (BSMI).
Expert review in Eyenet of corneal cross-linking as an adjunctive treatment for infectious keratitis and corneal melting.
Our latest review on corneal cross-linking (CXL), published in Progress in Retinal and Eye Research, explores its evolution, advanced protocols like ELZA-PACE, and clinical applications.
Visit ELZA Zurich HB, our modern eye clinic in Zurich Hauptbahnhof. Find us at Bahnhofplatz 15, 2nd floor, Ostrisalit – above The Counter.
From corneal cross-linking technology to sustainable clinical models, Nikki Kristoffersen-Hafezi discusses how evidence-based innovation and education can expand access to modern ophthalmic care.
A significant part of the symposium was dedicated to showcasing collaborative initiatives between Switzerland and Uzbekistan, particularly in healthcare. One example was a keratoconus screening initiative led by Ms. Nikki Hafezi, ELZA’s CEO, and a graduate of ETH Zürich and the University of Bern. This project, undertaken with local NGOs, provided vision screenings to 117 families, identifying three children with keratoconus. These children received further medical consultations and guidance for managing the condition.
Progress in ophthalmology depends not only on innovation, but on the structures that allow innovation to be tested, validated, and translated into clinical care. An
Experts explain how screen time affects the cornea and tear film, why the retina is not harmed, and what helps protect eye health.
Prof. Farhad Hafezi from the ELZA Institute provided an insightful update on the Second Global Consensus on Keratoconus during an interview with EyeTube.
